Skip to main content
2238 search results for:

Exemestane 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Exemestane | News

    Exemestane

    Musculoskeletal abnormalities
  2. Open Access 23-04-2024 | Exemestane | Online First

    Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane

    Antihormonal therapy is one of the mainstays in the treatment of estrogen receptor (ER) positive breast cancer, comprising 70–80% of all cases. During the last two decades, aromatase inhibitors (AIs) of the “third generation” pushed aside earlier …

  3. 01-12-2023 | Exemestane | News

    Exemestane/Ribociclib

    Subacute cutaneous lupus erythematosus
  4. Open Access 01-12-2023 | Breast Cancer | OriginalPaper

    XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

    Endocrine therapy has been the established treatment for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced breast cancer for many years. More recently, addition of cyclin-dependent kinase …

  5. 01-10-2023 | Hydroxychloroquine | News

    Exemestane

    Acute generalised exanthematous pustulosis: case report
  6. 01-08-2023 | Tenosynovitis | News

    Anastrozole, exemestane, letrozole: risk of tendon disorders

  7. 01-11-2022 | Breast Cancer | News

    Exemestane/letrozole/ribociclib

    Hepatic toxicity, haematological toxicity and lack of efficacy: 2 case reports
  8. 01-10-2022 | Exemestane | News

    Exemestane

    Lack of efficacy: case report
  9. 01-07-2022 | Exemestane | News

    Exemestane/sirolimus

    Pulmonary toxicity and lack of efficacy: case report
  10. Exemestane/zoledronic-acid

    Lack of efficacy: case report
  11. 01-12-2021 | Hyperpigmentation | News

    Exemestane/letrozole/pamidronic acid/tamoxifen

    Lack of efficacy: case report
  12. Open Access 01-12-2022 | Mesothelioma | Erratum

    Retraction Note: Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

    This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-13-69.

  13. 18-01-2023 | Mastectomy | OriginalPaper

    Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

  14. 01-02-2022 | Breast Cancer | ReviewPaper

    Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence

    Estrogen receptor-positive (ER+) breast cancer (BC) represents the predominant molecular subtype (~ 80%) of BC for which the main treatment strategy involves endocrine manipulation [ 1 ]. Depending on the menopausal status, there are different …

  15. 01-10-2020 | Metastasis | News

    Exemestane/palbociclib

    Pseudoprogression of metastatic breast cancer: case report
  16. 01-10-2020 | Liver Function Test | News

    Exemestane

    Cholestatic liver injury : case report
  17. Open Access 01-12-2021 | Pharmacokinetics | OriginalPaper

    Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

    The goal of treatment for patients with advanced or metastatic breast cancer (BC) is to control the disease, prolong survival, and improve quality of life. In hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative …

  18. Open Access 01-12-2021 | Breast Cancer | OriginalPaper

    Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC

    Everolimus (EVE), an oral mammalian rapamycin (mTOR) inhibitor, exerts antitumor effects against various cancers including breast cancer and renal cell carcinoma [ 1 , 2 ]. Since the BOLERO-2 study, EVE and exemestane (EXE) have been approved by …

  19. 01-12-2021 | Breast Cancer | Original Research

    Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

    Breast cancer remains the most common cancer and the second most common cause of cancer death in women. Metastatic breast cancer is not curable, and the overall survival (OS) at 5 years is 27% [ 1 ]. Approximately 75% of breast cancers are hormone …

  20. 01-12-2021 | Metastasis | Original Research

    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    Standard treatment for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor (HER2)-negative advanced breast cancer is endocrine therapy, using an aromatase inhibitor (AI; e.g. letrozole, anastrozole …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.